Vikram Deshpande
Overview
Explore the profile of Vikram Deshpande including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
362
Citations
16287
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Pankaj A, Yilmaz O, Deshpande V, Yilmaz O
Hum Pathol
. 2025 Feb;
155:105737.
PMID: 39988058
Locally advanced colorectal cancers are treated with neoadjuvant therapy (NAT), which has been shown to alter the characteristics of the tumor including size, lymph node yield, and histologic grade. We...
2.
3.
Nielsen M, Wolters J, Bringas O, Jiang H, Di Stefano L, Oghbaie M, et al.
Mob DNA
. 2025 Feb;
16(1):3.
PMID: 39915890
Background: Both the expression and activities of LINE-1 (L1) retrotransposons are known to occur in numerous cell-types and are implicated in pathobiological contexts such as aging-related inflammation, autoimmunity, and in...
4.
Yilmaz O, Arora K, Lee S, Hosseini S, Chen F, Padmanabha N, et al.
J Clin Pathol
. 2025 Jan;
PMID: 39788729
Aims: WNT signalling pathway dysregulation is often a critical early component in colorectal neoplasia, particularly the chromosomal instability pathway. Using two WNT reporters, and , we sought to assess whether...
5.
Hong S, Qian X, Deshpande V, Kulkarni S
bioRxiv
. 2025 Jan;
PMID: 39763767
Gastrointestinal (GI) motility is regulated in a large part by the cells of the enteric nervous system (ENS), suggesting that ENS dysfunctions either associate with, or drive GI dysmotility in...
6.
Petruch N, Bolm L, Nebbia M, Arya S, Ventin M, Qadan M, et al.
Anticancer Res
. 2024 Dec;
45(1):189-199.
PMID: 39740812
Background/aim: Predictors of recurrence following resection of hepatocellular carcinoma (HCC) are not fully established. This study investigated potential risk factors and prognostic scores for this situation. Patients And Methods: In...
7.
Goeppert B, Zen Y, Valle J, Klimstra D, Deshpande V
J Clin Pathol
. 2024 Dec;
PMID: 39674584
No abstract available.
8.
You E, Danaher P, Lu C, Sun S, Zou L, Phillips I, et al.
Cell
. 2024 Oct;
187(25):7232-7247.e23.
PMID: 39383862
Aberrant expression of repeat RNAs in pancreatic ductal adenocarcinoma (PDAC) mimics viral-like responses with implications on tumor cell state and the response of the surrounding microenvironment. To better understand the...
9.
Lu C, Pankaj A, Raabe M, Nawrocki C, Liu A, Xu N, et al.
Hepatol Commun
. 2024 Sep;
8(10).
PMID: 39330965
Background: HCC is a highly vascular tumor, and many effective drug regimens target the tumor blood vessels. Prior bulk HCC subtyping data used bulk transcriptomes, which contained a mixture of...
10.
Vijay V, Karisani N, Shi L, Hung Y, Vu P, Kattel P, et al.
bioRxiv
. 2024 Jul;
PMID: 39026794
Biliary tract cancers (BTCs) are a group of deadly malignancies encompassing intrahepatic and extrahepatic cholangiocarcinoma, gallbladder carcinoma, and ampullary carcinoma. Here, we present the integrative analysis of 63 BTC cell...